What’s ‘Neo’ in Treatment Options for Resectable NSCLC?

“In a 2025 JAMA Network Open invited commentary, Melina E. Marmarelis, MD, MSCE, and Lauren Reed-Guy, MD, both of the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, noted that immunotherapy (IO) ‘has transformed the management’ of resectable, early-stage non-small cell lung cancer (NSCLC).

They also name-checked the NeoADAURA trial as one that will continue to move NSCLC treatment forward, pointing out that testing for ‘ALK and EGFR will be crucial,’ because ‘patients who harbor these genetic alterations have lower response rates to immunotherapy and should preferentially receive targeted therapies in the adjuvant setting.’

‘This testing will only become more important as we start to see targeted therapy entering the neoadjuvant space,’ as is being done in NeoADAURA, the authors added.”

Read more at MedPage Today.